Sanguina’s AnemoCheck Home Hemoglobin Test Earns FDA Nod

Sanguina has gained U.S. Food and Drug Administration (FDA) clearance for its AnemoCheck Home, a home hemoglobin test.
 
The test aims to empower patients with anemia due to nutritional deficiency (iron deficiency anemia, vitamin B12 deficiency anemia, and folate deficiency anemia), sickle cell disease, and thalassemia to monitor their hemoglobin levels at home.
 
Accurate hemoglobin levels can be obtained via a fingerstick blood test. Once the finger stick is performed, blood is collected into a collection tube, then a test cap is connected to the test body. The user shakes the test to mix the blood, and after two minutes the color correlates to a hemoglobin level on a color card.
 
The test is disposable and doesn’t need any additional equipment.
 
Erika Tyburski, CEO of Sanguina told the press, “Our team at Sanguina is proud to introduce AnemoCheck Home as a game-changer for at-home anemia testing. With this FDA clearance, we are excited to provide people who have anemia with a convenient, accurate, and accessible tool to monitor their hemoglobin levels at home.”
 
Earlier this week, the company completed a Series A funding round of $2.8 million.